DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Integrilin (Eptifibatide) - Summary



Eptifibatide is a cyclic heptapeptide containing six amino acids and one mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties.

INTEGRILIN is indicated:

  • For the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction) including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction.
  • For the treatment of patients undergoing PCI, including those undergoing intracoronary stenting. In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention.

See all Integrilin indications & dosage >>


Media Articles Related to Integrilin (Eptifibatide)

Retinal Artery Occlusion May Increase Risk for ACS
Source: Medscape Ophthalmology Headlines [2014.09.11]
Patients with retinal artery occlusion (RAO) may be at increased risk for acute coronary syndrome (ACS), new research from Taiwan suggests.
Reuters Health Information

Anti-inflammatory treatment darapladib fails to prevent cardiac events - Solid-TIMI 52 trial results
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.09.03]
A new phase III study evaluating the investigational agent darapladib in patients with an acute coronary syndrome (heart attack or unstable angina) has failed to show a reduction in major coronary...

more news >>

Published Studies Related to Integrilin (Eptifibatide)

Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. [2011.02.22]
CONCLUSIONS: Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography. The benefit-risk ratio of intensive platelet inhibition with combined early use of antiplatelet agents needs further evaluation in prospective randomized trials.

Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention. [2011.01]
BACKGROUND: There is no head-to-head comparison between tirofiban versus eptifibatide in patients undergoing percutaneous coronary intervention (PCI) when added to standard antiaggregating drugs (AAD) to prevent ischemic events within 1 year... CONCLUSION: Head-to-head comparison between eptifibatide and tirofiban in patients undergoing PCI while on double AAD showed that eptifibatide had a lower efficacy on the incidence of composite ischemic events within 1 year, which might be explained by a reduced action on CK-MB pre-PCI.

Comparison of Ecchymosis Rates With Measurement of Automated and Manual Blood Pressures in Patients Receiving Eptifibatide Therapy. [2010.12.01]
CONCLUSIONS:: In 44 post-coronary interventional procedure patients on eptifibatide therapy, ecchymosis occurred in 9% of arms with automated BP measurement and 14% of arms with manual BP measurement during the 24-hour study period. This difference was not statistically significant. No other complications were observed. This study found that the overall incidence of complications from BP measurement was low and not related to whether the device used was an automated or manual BP device in post-coronary interventional procedure patients on eptifibatide therapy. Based on this study and a prior one, the reluctance of clinicians to use automated BP devices in post-procedural coronary intervention patients because of fears of increased tissue bleeding does not appear scientifically justified.

Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). [2010.08.03]
OBJECTIVES: The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). BACKGROUND: Glycoprotein IIb/IIIa inhibitors are recommended by international guidelines in patients with acute coronary syndromes undergoing PCI. Abciximab is recommended with a higher level of evidence than eptifibatide in patients with STEMI. No large, prospective, randomized trial comparing abciximab and eptifibatide has been published... CONCLUSIONS: This large registry study suggests that eptifibatide is noninferior to abciximab in patients with STEMI undergoing primary PCI with respect to death or MI during 1 year, thereby supporting the use of either drug in clinical practice. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. [2010.08.03]
OBJECTIVES: The aim of this study was to compare eptifibatide and abciximab as adjuncts to primary percutaneous coronary intervention (PCI). BACKGROUND: The glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab as adjunct to primary PCI in patients with ST-segment elevation myocardial infarctions has been shown to reduce ischemic complications and improve clinical outcomes. So far, no trial has been performed to compare the efficacy of another GP IIb/IIIa receptor inhibitor, eptifibatide, and abciximab in primary PCI... CONCLUSIONS: Eptifibatide as an adjunct to primary PCI is equally as effective as abciximab with respect to STR. (Efficacy of Eptifibatide Compared to Abciximab in Primary Percutaneous Coronary Intervention [PCI] for Acute ST Elevation Myocardial Infarction [STEMI]; NCT00426751). Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

more studies >>

Clinical Trials Related to Integrilin (Eptifibatide)

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease [Recruiting]
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems of sickle cell disease. Sickle cell disease has been referred to both as a condition associated with increased risk of blood clots and increased inflammation. A painful crisis represents the most common cli nical problem in sickle cell disease, but the treatment of these crises remains inadequate.

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke [Recruiting]
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome than individuals treated with standard IV rt-PA alone.

Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis [Recruiting]
This is an investigator sponsored double-blinded, multinational, multi center, randomized (2: 1 active: placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating the safety and efficacy of co-administration of Iloprost and escalating doses of Eptifibatide for continuous intravenous infusion in totally 36 patients.

Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients [Not yet recruiting]
The achievement of high local concentration of Eptifibatide, a GP 2b3a inhibitor,via direct intracoronary injection, promotes (in vitro) clot disaggregation. It remains unclear if it is of superior benefit than the routine intravenous administration of these agents.

In patients presenting with acute myocardial infarction, and undergoing primary coronary intervention, intracoronary administration of Eptifibatide may increase local drug concentration by several orders of magnitude and promote clot disaggregation with a minimal increase in systemic drug concentration, and in that way enhancing myocardial perfusion and survival.

Shortened Aggrastat� Versus Integrilin in Percutaneous Coronary Intervention [Recruiting]
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.

more trials >>

Reports of Suspected Integrilin (Eptifibatide) Side Effects

Thrombocytopenia (15)Haemoptysis (5)Haemorrhage (4)Death (4)Cardiogenic Shock (3)Endotracheal Intubation (3)Anaphylactic Shock (2)Pyrexia (2)Peripheral Ischaemia (2)Blood Culture Positive (2)more >>

Page last updated: 2014-09-11

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014